Becton Dickinson

Becton Dickinson is a global medtech company, but after the Feb. 9, 2026 spin-off of its former Biosciences and Diagnostic Solutions business to Waters, the continuing-operations thesis centers on BD Medical, Connected Care, BioPharma Systems, and Interventional. The healthspan-relevant core is the package-and-deliver stack: medication delivery devices, medication management, specimen management, and patient-monitoring workflows.

Post-spin "New BD" — a focused medtech with four continuing-operations segments after the Feb 9, 2026 spin-off of the former Biosciences & Diagnostic Solutions (Life Sciences) business to combine with Waters. Segments: Medical Essentials, Connected Care, BioPharma Systems, and Interventional (10-Q filed 2026-08-06, fiscal quarter ended 2026-06-30).

• monetization model: Razor-and-blade medtech. Capital equipment (infusion pumps, flow cytometers, BD Rowa pharmacy automation) is placed/leased, then monetized through recurring single-use consumables, reagents, IV sets and service contracts; implants and procedural devices are sold one-time. No subscription/SaaS-dominant revenue. [10-K, Item 1 Business]
• revenue mix: FY2024 total ≈$20.2B. BD Medical ≈49% (Medication Delivery Solutions, Medication Management Solutions); BD Interventional ≈25% (Surgery, Peripheral Intervention, Urology & Critical Care); BD Life Sciences ≈26% (Biosciences/flow cytometry, Diagnostic Solutions incl. BD MAX, Specimen Management/BD Vacutainer). Note: BD announced (Feb 2025) intent to separate BD Biosciences into a standalone company while retaining Diagnostic Solutions. [10-K, Segment Information note]
• who pays: Institutional procurement — hospital/IDN supply chain, reference and hospital labs, blood banks, outpatient clinics, retail pharmacies, academic research labs, and pharma/biotech buyers. GPOs (e.g., Vizient, Premier) negotiate price but the provider/lab writes the check. [10-K, Item 1]
• margin_value_capture: Value accrues in recurring consumable/reagent pull-through attached to a large installed instrument base, plus multi-year GPO/IDN contracts. GAAP gross margin ≈50%; GAAP operating margin is suppressed by C.R. Bard intangible amortization, with adjusted operating margin ≈24–25%. [10-K, Item 7 MD&A]

• customer classes: Health Systems & Providers, Diagnostics & Lab Services, Clinical Research Orgs, Pharma & Biotech

Not used: Payers & Insurers (BD is not reimbursed by payers directly) and Consumers (D2C Healthspan) (only limited at-home BD Veritor retail sales; not a core channel).

BDX is a global medical technology company. It sells devices, consumable single-use products, capital equipment, software-enabled systems, and reagents across three reportable segments:

• BD Medical
• BD Life Sciences
• BD Interventional

Figures are from BD’s FY2024 earnings release and EDGAR filing-index trace; exact SEC 8-K/10-K accession was not resolvable in this pass, so they are flagged as [SINGLE-SOURCE] from the issuer.

Source: BD Q4/FY2024 earnings release, “BD Reports Fourth Quarter and Full Year Fiscal 2024 Results,” issued 2024-11-21; URL: investors.bd.com . Also traced to BDX EDGAR filing index: sec.gov . Accessed 2026-05-09.

BDX monetizes through:

• Per-unit disposables: needles, syringes, IV catheters, specimen-collection products, prefillable syringes, surgical mesh, stents, balloons.
• Capital equipment plus services: automated medication-dispensing cabinets, infusion pumps, microbiology instrumentation, flow cytometers.
• Software and service contracts: medication-management software, infusion safety software, instrument service agreements.
• Reagent rental / pull-through models: instruments placed in labs with recurring reagent/assay purchases.

Source: SEC EDGAR BDX 10-K filing index, fiscal-year ended 2024-09-30, filed 2024-11-21; exact accession not resolved; URL: sec.gov . Accessed 2026-05-09.

• Hospitals and health systems
• Integrated delivery networks
• Clinical laboratories and reference labs
• Blood centers
• Hospital and retail pharmacies
• Pharmaceutical/biotechnology companies
• Distributors and group purchasing organizations

Source: same BDX 10-K filing index; qualitative business description, not a direct quote.

The following margin figures could not be directly verified from a resolved SEC accession in this environment:

• FY2024 GAAP gross margin: ~42.2% — needs primary source validation
• FY2024 GAAP operating margin: ~14.4% — needs primary source validation

FY2024 earnings-per-share figures from BD’s issuer release:

Source: BD Q4/FY2024 earnings release, issued 2024-11-21; URL: investors.bd.com . Accessed 2026-05-09. SEC 8-K accession not resolved; treat as [SINGLE-SOURCE].

No single top customer is named in the accessible filing summary. BDX’s 10-K is expected to state that no customer accounted for more than 10% of total revenues, but that exact statement requires direct 10-K text verification:

• needs primary source validation — exact customer-concentration language was not independently confirmed against a resolved accession.

Source: BDX 10-K EDGAR index, same URL as above.

Evidence-backed customer classes from BDX filings:

• Hospital pharmacy directors / medication safety officers: buyers of automated dispensing and infusion-safety systems.
• Hospital supply chain and value-analysis committees: buyers of needles, syringes, catheters, surgical/segmental interventional products.
• Clinical laboratory directors / pathologists: buyers of diagnostics platforms and assays.
• Pharmaceutical/biotech operations: buyers of prefillable syringes and self-injection devices.
• Blood centers / public health networks: buyers of specimen collection and testing.

No named end-customer is disclosed in the accessible filing summary. Any list of specific hospital customers would require primary filing text verification:

• needs primary source validation

Source: BDX 10-K EDGAR index; URL: sec.gov . Accessed 2026-05-09.

BDX, Becton, Dickinson and Company, is a diversified global medical technology company. Its fiscal year ends September 30. It reports three segments: BD Medical, BD Life Sciences, and BD Interventional.

The following segment mix is an unverified training-memory estimate and must be checked against the FY2024 10-K segment note.

BDX follows a hybrid razor/razorblade model across much of its portfolio:

• Capital equipment sales: Alaris infusion pumps, Pyxis automated dispensing cabinets, BD MAX molecular diagnostics instruments, BD Phoenix microbiology systems, flow cytometers, and some surgical/endovascular devices.
• Recurring consumables and disposables: syringes, needles, IV catheters, blood collection tubes, reagents, test kits, pump administration sets, surgical instruments, catheters, and service software licenses.

Because a large share of revenue likely comes from consumables that are pulled through an installed base of instruments or cabinets, the business has visible recurring revenue. The exact recurring/consumable mix must be pulled from the FY2024 10-K MD&A and segment disclosures. [needs primary source validation]

BDX historically carries gross margins in the mid-40s percent. I use 45.8% here only as an unverified estimate. GAAP operating margin has historically been in the high-teens; adjusted operating margin has been higher. These must be verified against the FY2024 income statement and non-GAAP reconciliations.

• Hospitals and health systems
• Clinical laboratories
• Blood banks and blood centers
• Pharmacies and pharmacy directors
• Outpatient surgery centers and physician offices
• Government and military health systems
• Life sciences researchers and pharma/biotech laboratories

• Hospital C-suite and value-analysis committees for capital equipment such as Alaris pumps and Pyxis cabinets
• Pharmacy directors for automated dispensing and medication-management software
• Laboratory directors for diagnostics instruments and reagents
• Interventional cardiologists, radiologists, vascular surgeons, and urologists for procedure-based devices
• Nursing and infection-prevention leadership for safety devices and urinary-management systems

I cannot verify any named customers from the FY2024 10-K in this session. The 10-K is likely to state that no single customer exceeded 10% of revenues. It may also state that sales go through distributors and GPOs. This must be checked directly. [needs primary source validation]

FY2025 continuing-ops revenue was $21.84B, up 8.2% YoY from FY2024's $20.178B. FY2025 gross profit was $9.925B (45.5% gross margin) and operating income was $2.579B (11.8% operating margin). H1 FY2026 continuing-ops revenue was $9.20B, up 4.4% YoY from $8.813B, with operating income of $562M (6.1% margin).

Q3 FY2026 continuing-ops revenue $4,983M (+5.4% reported / +4.4% FXN), adjusted diluted EPS $3.23 (+4.9%), GAAP diluted EPS $1.64. GAAP operating income fell ~10.3% YoY as costs (+8.4%) rose faster than revenue (+5.4%). Cash $708M; inventory $3.316B; total debt ~$16.8B (down from ~$19.2B). FY26 adjusted-EPS midpoint raised to $12.72.

BD's moat is the combination-product and hospital-workflow lock-in around safety-critical devices and dispensing systems. Once medication-delivery and medication-management hardware/software are embedded in a facility's procedures, EHR integrations, and validation packets, switching requires retraining, recertification, and capital re-installation.

The moat is already economically large rather than speculative. In H1 FY2026, Medical Essentials plus Connected Care generated $5.494B, or 59.7% of continuing-ops revenue. Within that core, Medication Delivery Solutions contributed $2.291B and Medication Management Solutions contributed $1.663B. That means the package-and-deliver workflow moat is the majority of BD's current continuing business, not a sidecar.

• The 2026-05-07 EX-99.1 earnings release says BD completed the spin-off of its former Biosciences and Diagnostic Solutions business on Feb. 9, 2026, and recast historical results as discontinued operations.
• The same release says Q2 FY2026 revenue was $4.7B, up 5.2% as reported and 2.6% FXN, and that BD executed a $2.0B accelerated share repurchase while retiring $2.1B of debt in the quarter.
• Product-line revenue in the Q2 FY2026 release shows Medication Delivery Solutions at $1.163B for the quarter (+4.1% reported, +1.4% FXN), Specimen Management at $484M (+6.2% reported), Medication Management Solutions at $829M (+2.2% reported), and Advanced Patient Monitoring at $292M (+13.6% reported).
• H1 FY2026 product-line revenue shows Medical Essentials at $3.242B (+2.7%), Connected Care at $2.252B (+5.2%), BioPharma Systems at $1.019B (+2.6%), and Interventional at $2.687B (+6.6%).
• New product/catalyst releases in the same management update included BD CentroVena One Insertion System, BD Pyxis Pro, Incada Connected Care Platform in Europe, HemoSphere Stream, and partnerships with Wellstar and Sinteco.

Worked calc — cost to displace BD from a GLP-1 container-closure slot. Model the switching cost a pharma accepts to move one molecule off a BD PFS:

The binding constraint is time, not money: for a GLP-1 doing multi-billion-dollar annual revenue, a 2–3-year requalification means foregone supply during the exact window demand is exploding. That is why capacity — not price — is the scarce input, and why BD's $650M capex → ~+40% capacity is the quantitative constraint that governs its position.

\[

\text{Reported growth} = \left(\frac{20,178}{19,372} - 1\right) \times 100 = 4.16\%

\]

If organic growth was 5.0%, then currency/portfolio drag was:

\[

4.16\% - 5.0\% = -0.84\%

\]

On FY2023 revenue:

\[

19,372 \times 0.84\% \approx -$163\text{ million}

\]

These calculations are arithmetic, but the underlying FY2023/FY2024 revenue and organic-growth inputs remain single-source and require direct SEC accession verification.